Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/E ratio high or low?
The P/E ratio of 326.19 is in line with its 1-year average of 351.15, near the low end of its 1-year range (307.46–396.67).
As of 2026-10-06T15:43:04.669Z.
Calculation as of: 2026-10-06T15:43:04.669Z.
Quote observation: 2026-10-06T15:40:34.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 30dfce3917ca71ab065f09e043ba83ae01990a938fe51dfc801fb26557bc7c3c
PE Ratio (326.19) = Close Price ($20.55) / Diluted TTM EPS ($0.06)
PE RATIO
326.19
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
25.56
median of 168 covered companies
CURRENT VS SECTOR MEDIAN
+1175.92%
vs the sector median at left
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Omada Health (OMDA) | $1.22B | 326.19 | N/A | N/A | N/A |
| MannKind Corporation (MNKD)vs › | $1.22B | N/A | 65.92 | 100.90 | 100.90 |
| Innovage Holding Corp. (INNV)vs › | $1.22B | N/A | 92.39 | 92.39 | 92.39 |
| Cronos Group Inc. (CRON)vs › | $1.23B | 18.11 | 29.62 | 28.16 | 28.16 |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.25B | N/A | N/A | N/A | N/A |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.17B | N/A | N/A | N/A | N/A |
| Kardigan, Inc. (KARD)vs › | $1.28B | N/A | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.16B | N/A | 10.01 | 10.01 | 83.50 |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.15B | N/A | N/A | N/A | N/A |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 78.24 | 42.78 | 72.87 | 84.11 |
At 326.2, P/E is at an extreme level, where the multiple carries little signal — higher than 30% of readings in its 1-year history.
1-year low
307.5
median
352.9
1-year high
396.7
Trailing P/E
326.2
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$20.55
Forward EPS (Est.)
$0.33
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2026-10-05 | 332.54 |
| 2026-10-02 | 323.33 |
| 2026-10-01 | 323.97 |
| 2026-09-30 | 330.32 |
| 2026-09-29 | 307.46 |
| 2026-09-28 | 307.78 |
| 2026-09-25 | 312.06 |
| 2026-09-24 | 313.02 |
| 2026-09-23 | 328.41 |
| 2026-09-22 | 339.21 |
| 2026-09-21 | 327.14 |
| 2026-09-18 | 324.29 |
| 2026-09-17 | 314.76 |
| 2026-09-16 | 313.65 |
| 2026-09-15 | 312.22 |
| 2026-09-14 | 325.40 |
| 2026-09-11 | 312.06 |
| 2026-09-10 | 341.27 |
| 2026-09-09 | 341.27 |
| 2026-09-08 | 352.06 |
| 2026-09-04 | 361.43 |
| 2026-09-03 | 353.81 |
| 2026-09-02 | 370.00 |
| 2026-09-01 | 362.54 |
| 2026-08-31 | 389.68 |
| 2026-08-28 | 376.03 |
| 2026-08-27 | 385.24 |
| 2026-08-26 | 380.32 |
| 2026-08-25 | 380.00 |
| 2026-08-24 | 382.22 |
| 2026-08-21 | 379.21 |
| 2026-08-20 | 376.35 |
| 2026-08-19 | 388.41 |
| 2026-08-18 | 376.98 |
| 2026-08-17 | 376.98 |
| 2026-08-14 | 381.59 |
| 2026-08-13 | 386.83 |
| 2026-08-12 | 378.41 |
| 2026-08-11 | 381.11 |
| 2026-08-10 | 396.67 |